Activity of telithromycin against multi-drug resistant Streptococcus pneumoniae and molecular characterization of macrolide and tetracycline resistance determinants

Journal of Chemotherapy

Volumn 17, Issue 5, 2005, Pages 502-508

  Cascone, C ^a   Mezzatesta, M L ^a   Santagati, M ^a   Cafiso, V ^a   Nicoletti, G ^a   Stefani, S ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Macrolide resistance genes; Multi drug resistance; S. pneumoniae; Telithromycin

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; CEFUROXIME; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; JOSAMYCIN; LEVOFLOXACIN; MACROLIDE; PENICILLIN DERIVATIVE; TELITHROMYCIN; TETRACYCLINE; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; ERM GENE; GENE; GENOTYPE; HUMAN; ITALY; MEF GENE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; STRAIN DIFFERENCE; STREPTOCOCCUS PNEUMONIAE; TET GENE;

EID: 28144445001     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.5.502     Document Type: Article

References (24)

1. Stefani S. Emergence of multi-drug resistance Gram-positive bacteria and new active antibiotics. Curr Med Chem 2005; 4.
2. Schito AM, Marchese A, Elkharrat D, Farrell DJ, and The PROTEKT Study Group. Comparative activity of telithromycin against macrolide-resistant isolates of Streptococcus pneumoniae: results of two years of the PROTEKT surveillance study. J Chemother 2004; 16 (1): 13-22.
3. Del Grosso M, Scotto d'Ambruso A, Iannelli F, Pozzi G, Pantosti A. Tn2009, a Tn916-like element containing mef(E) in S.pneumoniae. Antimicrob Agents Chemother 2004; 48(6): 2037-2042.
4. Speirs KM, Zervos MJ. Telithromycin. Exp Rev Antiinfective Ther 2004; 2 (5): 685-693.
5. Matic V, Kosowska K, Bozdogan B et al. Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin. Antimicrob Agents Chemother 2004; 48: 4103-4112.
6. Karchmer AW. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US - an update. Clin Infect Dis 2004; 39: S142-150.
7. Balfour JA, Figgitt DP - Telithromycin. Drugs 2001; 61: 815-29.
8. th Ed 2003 ASM press Washington DC, USA.
9. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. CLSI M7-A6. CLSI, Wayne, PA, USA. 2005.
10. Cascone C, Santagati M, Noviello S et al. Macrolide resistance genes in Italian clinical isolates of Streptococcus pyogenes Microb Drug Resist 2002; 88(2): 129-132.
11. McDougal LK, Tenover FC, Lee LN et al. Detection of Tn917-like sequences within a Tn916-like conjugative transposon (Tn3872) in erythromycin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998; 42: 2312-2318.
12. Pitcher DG, Sanders NA, Owen RJ. Rapid extraction of bacterial genomicDNA with guanidium thiocyanate. Lett Appl Microbiol 1989; 8: 151-156.
13. Santagati M, Iannelli F, Cascone C et al. The novel conjugative transposon Tn1207.3 carries the macrolide efflux gene mef(A) in Streptococcus pyogenes. Microb Drug Resist 2003; 9: 243.
14. Tenover FC, Arbeit RD, Goering RV et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33 (9): 2233-2239.
15. th ICAAC - Washington DC October 30, 2004.
16. Felmingham D, Reinert RR, Hirakata Y, Rodloff A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of ketolide, telithromycin. J Antimicrob Chemother 2002; 50, Suppl. S1, 25-37.
17. Marchese A, Tonoli E, Debbia EA, Schito GC. Macrolide resistance mechanisms and expression of phenotypes among Streptococcus pneumoniae circulating in Italy. J Antimicrob Chemother 1999; 44(4): 461-464.
18. Monaco M, Cavilli R, D'Ambrosio F, Del Grosso M, Pantosti A. Evolution of erythromycin resistance in Streptococcus pneumoniae in Italy. J Antimicrob Chemother 2005; 55(2): 256-259.
19. Whitney CG, Parley MM, Hadler J et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. New Engl J Med 2000; 343: 1917-1924.
20. Marchese AM, Tonoli E, Balistreri G, Debbia E, Schito GC. Antibiotic susceptibility patterns and serotypes of antibiotic resistant and/or invasive Streptococcus pneumoniae strains circulating in Italy. Microb Drug Resist 2000; 2: 163-169.
21. Montanari MP, Cochetti I, Mongoia M, Varaldo PE. Phenotypic and molecular characterization of tetracycline- and erythromycin-resistant strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 2003; 47: 2236-2241.
22. Schmitz FJ, Perdikouli M, Beeck A, Verhoef J, Fluit AC. Resistance to trimethoprim-sulfamethoxazole and modifications in genes coding for dihydrofolate reductase and dihydropteroate synthase in European Streptococcus pneumoniae isolates. J Antimicrob Chemother 2001; 48: 931-942.
23. Brown SD, Farrell DJ, Morrisey I. Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 200-2001 PROTEKT US Study. J Clin Microbiol 2004; 42: 4980-4987.
24. Montanari MP, Tili E, Cochetti I, Mingoia M, Manzin A, Varaldo PE. Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy. Microb Drug Resist 2004; 10 (3): 209-217.